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PREVENTION AND REVERSAL OF LUPUS IN NZB/NZW MICE BY TRANS-
PLANTATION OF PURIFIED ALLOGENEIC HEMATOPOIETIC STEM CELLS
(HSC) WITH NON-MYELOABLATIVE CONDITIONING (NMT)
Smith-Berdan, S.1, Gille, D.1, Christensen, J.L.1 1Cellerant Therapeu-
tics, San Carlos, CA.
Systemic lupus erythematosus (SLE) is a multifactorial autoimmune
disease. Patients’ refractory to therapy may be considered for hema-
topoietic stem cell transplantation. Using lupus prone NZB x NZW
(NZBW) mice, we tested the ability of highly enriched, allogeneic
haplo-identical HSC to prevent and reverse autoimmune symptoms.
Ablative conditioning: Young, female NZBW mice were trans-
planted with puriﬁed haplo-identical allogeneic HSC, syngeneic HSC
or syngeneic WBM from age matched donors. Transplantation with
either syngeneic HSC or WBM accelerated disease in these mice,
resulting in a rate of death exceeding agematched controls. Allogeneic
transplanted mice had signiﬁcantly greater overall survival (OS) above
all groups (P 0.0243), with 53% alive at 420 days of age. The
frequency of mice with proteinuria (14%), elevated levels of circulat-
ing immune complexes (CIC) (25%), and auto-antibodies to dsDNA
(39%), nuclear antigens (39%) and histones (46%) was lower in
allo-HSC transplanted animals compared to the mice transplanted
with syngeneic HSC or WBM and the age matched controls (74-
100%) (P 0.0001). NMT conditioning: To determine if we could
attenuate disease in NZBW mice already progressing into lupus-like
disease with transplantation of allogeneic, haplo-identical HSC and
reduce TRM, we developed a non-myeloablative conditioning proto-
col achieving an average mixed chimerism of 50%. Animals were
treated at 8 months of age with established symptoms of lupus (Table
1). While the group receiving conditioning alone, had a slight survival
advantage over age matched control mice, the mice transplanted with
allogeneicHSC had greatly increasedOSwith 60% living beyond 575
days of age (335 days from transplant). Allo-HSC transplanted mice
showed reversal or stabilization of their lupus symptoms including
proteinuria, CIC, dsDNA and histone. Conclusions: 1) Ablative and
NMT transplant can treat lupus; 2) OS after NMT exceeds ablative
conditioning; 3) Induction of durable mixed chimerism with puriﬁed
allogeneic HSC using NMT conditioning treats established lupus.
The ability of pure HSC transplant and establishment of durable
mixed chimerism to reverse established lupus makes it a reasonable
strategy to test in man.
Summary of survival, proteinuria & serology with NMT conditioning
NMT age@Tx241
days
Age
matched
control
Allogeneic
HSC
Conditioning
only
N 13 33 30
OS@0575 days of age 0 60% 0
Proteinuria@Tx 22% 45% 47%
Final Proteinuria 100% 30% 70%
CIC 89% 52% 73%
Anti-dsDNA 86% 55% 70%
Anti-Histone 100% 36% 62%
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NOD FC EXHIBIT SIGNIFICANTLY IMPAIRED FUNCTION
Fugier-Vivier, I.J.1, Huang, Y.1, Miller, T.1, Tanner, M.K.1,
Chilton, P.M.1, Ildstad, S.T.1 1Institute for Cellular Therapeutics, Uni-
versity of Louisville, Louisville, KY.
Induction of mixed allogeneic chimerism in humans and in pre-
diabetic NOD mice reverses the autoimmune process in type 1
diabetes. The administration of Flt3-ligand (FL) to NOD mice
decreases diabetes incidence and delays the onset of diabetes. One
mechanism by which both chimerism and FL treatment may re-
verse autoimmunity is through generation of dendritic cell (DC)
subsets lacking in NOD mice. In the present studies we character-
ized NOD FC function, comparing the ability of diabetes-resistant
NOR FC versus NOD FC to enhance NOD HSC engraftment in
NOD recipients. 500 NOD HSC (c-Kit/Sca-1/Lin-) were
sorted and transplanted with 30,000 NOR FC (HSCFC group,
n15) or without FC (HSC group, n21) into conditioned 950
cGy NOD recipients. The NOR FC strongly increased NOD
HSC engraftment compared to the HSC group alone (p  0.001).
By contrast, NOD FC did not improve NOD HSC engraftment in
NOD recipients as evidenced by the similar engraftment of 500
HSC with 30,000 FC (HSCFC group, n13) compared to the
NOD HSC group (n17). These results point without ambiguity
to a defect in NOD FC that is not present in the NOR FC. To
characterize the defect in the NOD FC population, we explored
the difference between NOD FC and functional NOR or B6 FC
composition of FC subpopulations. CD8/TCR- NOD FC were
sorted from bone marrow and the sorted FC were evaluated for
subpopulations we previously found in normal FC: NK cells
(DX5), myeloid cells (CD11b), B cells (CD19), monocytes (CD14),
and dendritic cells (CD11c). We found that precursor plasmacy-
toid dendritic cells (p-pre DC FC) represented the major FC
subpopulation in all strains examined. Interestingly, only the CD19
FC subpopulation was signiﬁcantly decreased in NOD FC com-
pared to those from B6 or NOR mice (12% versus 26%, P 0.05
from more than three separate experiments on 3-5 mice). From our
results, we hypothesize that the CD19 FC subpopulation could
represent the collaborative cell within the FC population that
synergizes with the p-preDC FC to provide an optimal facilitating
effect. Studies are in progress to determine whether FL-treatment
restores the CD19 FC population in NOD mice and determine
whether FL-treated NOD FC recover the ability to enhance HSC
engraftment. Our underlying hypothesis is that restoring function
to NOD FC will provide the milieu to induce the otherwise lacking
regulatory mechanisms and control the autoimmunity in diabetes.
Group HSC donor FC donor n
% survival over
120 days post
Tx
A NOD none 38 21
B NOD NOD 13 31
C NOD NOR 15 53
D none none 15 0
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HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) FOR AUTOIM-
MUNE DISEASES (AI): REVIEW OF TRANSPLANTS PERFORMED IN
NORTH AND SOUTH AMERICA AND REPORTED TO THE CENTER FOR
INTERNATIONAL BLOOD AND MARROW TRANSPLANTATION (CIBMTR)
Mcsweeney, P.A.1,5, Pasquini, M.C.2, Kukreja, M.2, Bredeson, C.2,
Nash, R.3, Horowitz, M.M.2, Atkins, H.4 1US Oncology Rocky Moun-
tain Cancer Center, Denver, CO; 2Medical College of Wisconsin, Mil-
waukee, WI; 3Fred Hutchinson Cancer Research Center, Seattle, WA;
4Otawa Hospital, Otawa, ON, Canada; 5on behalf of the CIBMTR
Autoimmune Working Committee.
The objective of high dose chemotherapy followed by hemato-
poietic stem cell rescue is to halt autoimmunity in patients with
severe AI. Few patients have received this treatment to date and
this report summarizes the activity of HCT for AI from centers in
North and South America. One-hundred and ninety-eight patients
who underwent HCT primarily for the treatment of AI, were
reported to the CIBMTR from 1996-2005 from 43 centers. Most
received an autologous HCT (autoHCT) (171 of 198). The most
common indications for autoHCT were multiple sclerosis (MS)
(45%), scleroderma (SSC) (35%) and systemic lupus erythematous
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